REG - GSK PLC - Ris-Rez positive Ph 3 osteosarcoma data in China

What happened

GSK said its partner Hansoh reported positive phase III results in China for Ris-Rez in relapsed osteosarcoma. The trial met its main goal: Ris-Rez cut the risk of disease progression or death by 67% versus chemotherapy, and patients stayed progression-free for a median of 5.5 months versus 1.4 months.

Confirmed

Global impact / market context

Positive late-stage data can raise expectations for Ris-Rez's future sales and support GSK's pipeline, while the licensed partner Hansoh gains a stronger case in China. For investors, this improves the perceived value of the drug programme but does not by itself confirm regulatory approval.

Analyst inference

Osteosarcoma is a bone cancer with limited options after relapse, so a meaningful survival benefit may draw clinical and commercial interest. This is a second positive phase III result in China for Ris-Rez, while GSK's global phase II trial in advanced osteosarcoma and soft tissue sarcoma continues.

Analyst inference

What to watch

1. The late-breaking ARTEMIS-011 results were presented, with progression-free survival assessed by an Independent Review Committee, which means an outside expert panel reviewed the scans. Watch for the full presentation details and any follow-up survival data. Confirmed
2. Watch whether GSK and Hansoh file for regulatory approval in China based on these data, which would move the drug from trial results toward a possible commercial launch and sales. Proposed
3. Track GSK's ongoing global phase II trial in advanced osteosarcoma and soft tissue sarcoma, since results there could show whether the benefit extends beyond China and support a larger development plan. Analyst inference

Evidence

• Original source link unavailable